Literature DB >> 19262957

The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma beta-amyloid isoforms using the INNO-BIA plasma Abeta forms multiplex assay.

D R Lachno1, H Vanderstichele, G De Groote, V Kostanjevecki, G De Meyer, E R Siemers, M B Willey, J S Bourdage, R J Konrad, R A Dean.   

Abstract

OBJECTIVE: The aim of the study was to determine the extent to which plasma matrix types, diurnal rhythm and sample collection and processing procedures contribute to overall variability of measurements with the INNO-BIA plasma Abeta forms assay.
METHODS: Plasma samples from healthy volunteers were collected at BARC-CRI. Analyte concentrations from various plasma matrix types (EDTA, heparin, fluoride) were compared to serum after collection of blood in commercial plastic and glass tubes. Sample processing variables including time and temperature before and after centrifugation, centrifugal force and plasma dilution factor were also investigated. Diurnal variability in plasma Abeta isoforms was determined in 29 healthy volunteers by analysis of EDTA plasma specimens serially collected over 24 hours and stored frozen following oral administration of a placebo treatment. All plasma samples from a given individual and experiment were analyzed in a single analytical run.
RESULTS: Highest Abeta levels were obtained using EDTA-plasma samples (in contrast to serum, heparin, citrate, or fluoride). Addition of aprotinin to EDTA plasma had no effect on Abeta peptide recovery. The elapsed time and temperature exposure, before and after sample processing affects the recovery of Abeta isoforms. Analyte recovery was not significantly affected by the presence of platelets in plasma samples. At the subject level, analysis of serially collected EDTA plasma specimens from healthy volunteers revealed no evidence of diurnal variation in any of the Abeta isoforms investigated and results from samples collected on a monthly basis showed only very limited intra-individual variation.
CONCLUSIONS: Optimal recovery of Abeta peptides was obtained from blood drawn into EDTA tubes and processed within 4 h. Plasma that was refrigerated after separation and analysed within 4 h gave comparable results to samples immediately processed and frozen at -70 degrees C.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19262957     DOI: 10.1007/s12603-009-0062-5

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  6 in total

1.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

Authors:  N Andreasen; C Hesse; P Davidsson; L Minthon; A Wallin; B Winblad; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Arch Neurol       Date:  1999-06

2.  Forecasting the global burden of Alzheimer's disease.

Authors:  Ron Brookmeyer; Elizabeth Johnson; Kathryn Ziegler-Graham; H Michael Arrighi
Journal:  Alzheimers Dement       Date:  2007-07       Impact factor: 21.566

3.  Public health premise for national research priorities: mortality versus disability.

Authors:  Zaven S Khachaturian; Ara S Khachaturian
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

4.  Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

Authors:  Neill R Graff-Radford; Julia E Crook; John Lucas; Bradley F Boeve; David S Knopman; Robert J Ivnik; Glenn E Smith; Linda H Younkin; Ronald C Petersen; Steven G Younkin
Journal:  Arch Neurol       Date:  2007-03

5.  Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets.

Authors:  Annika Olsson; Eugeen Vanmechelen; Hugo Vanderstichele; Pia Davidsson; Kaj Blennow
Journal:  Dement Geriatr Cogn Disord       Date:  2003       Impact factor: 2.959

6.  Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease.

Authors:  Nicole Schupf; Ming X Tang; Hide Fukuyama; Jennifer Manly; Howard Andrews; Pankaj Mehta; Jeffery Ravetch; Richard Mayeux
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-08       Impact factor: 11.205

  6 in total
  15 in total

1.  Editorial: CTAD International Research Conference: Clinical Trials in Alzheimer's Disease.

Authors:  S Gauthier
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

2.  Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI.

Authors:  Jon B Toledo; Hugo Vanderstichele; Michal Figurski; Paul S Aisen; Ronald C Petersen; Michael W Weiner; Clifford R Jack; William Jagust; Charles Decarli; Arthur W Toga; Estefanía Toledo; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski; Leslie M Shaw
Journal:  Acta Neuropathol       Date:  2011-07-30       Impact factor: 17.088

3.  Linkage analysis for plasma amyloid beta levels in persons with hypertension implicates Aβ-40 levels to presenilin 2.

Authors:  Carla A Ibrahim-Verbaas; Irina V Zorkoltseva; Najaf Amin; Maaike Schuur; Antonia M W Coppus; Aaron Isaacs; Yurii S Aulchenko; Monique M B Breteler; M Arfan Ikram; Tatiana I Axenovich; Marcel M Verbeek; John C van Swieten; Ben A Oostra; Cornelia M van Duijn
Journal:  Hum Genet       Date:  2012-08-08       Impact factor: 4.132

4.  Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β-Amyloid.

Authors:  Cheryl A Luis; Laila Abdullah; Ghania Ait-Ghezala; Benoit Mouzon; Andrew P Keegan; Fiona Crawford; Michael Mullan
Journal:  Int J Alzheimers Dis       Date:  2011-05-24

5.  Association between IgM anti-herpes simplex virus and plasma amyloid-beta levels.

Authors:  Catherine Féart; Catherine Helmer; Hervé Fleury; Yannick Béjot; Karen Ritchie; Philippe Amouyel; Susanna Schraen-Maschke; Luc Buée; Jean-Charles Lambert; Luc Letenneur; Jean-François Dartigues
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

6.  Biomarkers associated with delirium in critically ill patients and their relation with long-term subjective cognitive dysfunction; indications for different pathways governing delirium in inflamed and noninflamed patients.

Authors:  Mark van den Boogaard; Matthijs Kox; Kieran L Quinn; Theo van Achterberg; Johannes G van der Hoeven; Lisette Schoonhoven; Peter Pickkers
Journal:  Crit Care       Date:  2011-12-29       Impact factor: 9.097

7.  SORL1 gene, plasma biomarkers, and the risk of Alzheimer's disease for the Han Chinese population in Taiwan.

Authors:  Cheng-Ta Chou; Yi-Chu Liao; Wei-Ju Lee; Shuu-Jiun Wang; Jong-Ling Fuh
Journal:  Alzheimers Res Ther       Date:  2016-12-30       Impact factor: 6.982

8.  Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease.

Authors:  Anne M Fagan; Mark A Mintun; Aarti R Shah; Patricia Aldea; Catherine M Roe; Robert H Mach; Daniel Marcus; John C Morris; David M Holtzman
Journal:  EMBO Mol Med       Date:  2009-11       Impact factor: 12.137

Review 9.  Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research.

Authors:  Sid E O'Bryant; Veer Gupta; Kim Henriksen; Melissa Edwards; Andreas Jeromin; Simone Lista; Chantal Bazenet; Holly Soares; Simon Lovestone; Harald Hampel; Thomas Montine; Kaj Blennow; Tatiana Foroud; Maria Carrillo; Neill Graff-Radford; Christoph Laske; Monique Breteler; Leslie Shaw; John Q Trojanowski; Nicole Schupf; Robert A Rissman; Anne M Fagan; Pankaj Oberoi; Robert Umek; Michael W Weiner; Paula Grammas; Holly Posner; Ralph Martins
Journal:  Alzheimers Dement       Date:  2014-10-01       Impact factor: 21.566

10.  Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma.

Authors:  Virginia Pérez-Grijalba; Noelia Fandos; Jesús Canudas; Daniel Insua; Diego Casabona; Ana M Lacosta; María Montañés; Pedro Pesini; Manuel Sarasa
Journal:  J Alzheimers Dis       Date:  2016-09-06       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.